Schwarz DA, Katayama CD, Hedrick SM. Schlafen, a new family of growth regulatory genes that affect thymocyte development. Immunity. 1998;9(5):657–68.

Article  CAS  PubMed  Google Scholar 

Brady G, Boggan L, Bowie A, O’Neill LA. Schlafen-1 causes a cell cycle arrest by inhibiting induction of cyclin D1. J Biol Chem. 2005;280(35):30723–34.

Article  CAS  PubMed  Google Scholar 

Bustos O, Naik S, Ayers G, Casola C, Perez-Lamigueiro MA, Chippindale PT, Pritham EJ, de la Casa-Esperón E. Evolution of the Schlafen genes, a gene family associated with embryonic lethality, meiotic drive, immune processes and orthopoxvirus virulence. Gene. 2009;447(1):1–11.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Li M, Kao E, Gao X, Sandig H, Limmer K, Pavon-Eternod M, Jones TE, Landry S, Pan T, Weitzman MD, et al. Codon-usage-based inhibition of HIV protein synthesis by human schlafen 11. Nature. 2012;491(7422):125–8.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Neumann B, Zhao L, Murphy K, Gonda TJ. Subcellular localization of the Schlafen protein family. Biochem Biophys Res Commun. 2008;370(1):62–6.

Article  CAS  PubMed  Google Scholar 

van Zuylen WJ, Garceau V, Idris A, Schroder K, Irvine KM, Lattin JE, Ovchinnikov DA, Perkins AC, Cook AD, Hamilton JA, et al. Macrophage activation and differentiation signals regulate schlafen-4 gene expression: evidence for Schlafen-4 as a modulator of myelopoiesis. PLoS ONE. 2011;6(1):e15723.

Article  PubMed  PubMed Central  Google Scholar 

Zoppoli G, Regairaz M, Leo E, Reinhold WC, Varma S, Ballestrero A, Doroshow JH, Pommier Y. Putative DNA/RNA helicase Schlafen-11 (SLFN11) sensitizes cancer cells to DNA-damaging agents. Proc Natl Acad Sci U S A. 2012;109(37):15030–5.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Liu F, Zhou P, Wang Q, Zhang M, Li D. The schlafen family: complex roles in different cell types and virus replication. Cell Biol Int. 2018;42(1):2–8.

Article  CAS  PubMed  Google Scholar 

Jo U, Pommier Y. Structural, molecular, and functional insights into Schlafen proteins. Exp Mol Med. 2022;54(6):730–8.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Mavrommatis E, Fish EN, Platanias LC. The schlafen family of proteins and their regulation by interferons. J Interferon Cytokine Res. 2013;33(4):206–10.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Puck A, Aigner R, Modak M, Cejka P, Blaas D, Stöckl J. Expression and regulation of Schlafen (SLFN) family members in primary human monocytes, monocyte-derived dendritic cells and T cells. Res Immunol. 2015;5:23–32.

Article  Google Scholar 

Yu J, Guo Z, Zhang J. Research progress of the SLFN family in malignant tumors. Front Oncol. 2024;14:1468484.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Barretina J, Caponigro G, Stransky N, Venkatesan K, Margolin AA, Kim S, Wilson CJ, Lehár J, Kryukov GV, Sonkin D, et al. The cancer cell line encyclopedia enables predictive modelling of anticancer drug sensitivity. Nature. 2012;483(7391):603–7.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Hanahan D. Hallmarks of cancer: new dimensions. Cancer Discov. 2022;12(1):31–46.

Article  CAS  PubMed  Google Scholar 

Macheret M, Halazonetis TD. DNA replication stress as a hallmark of cancer. Annu Rev Pathol. 2015;10:425–48.

Article  CAS  PubMed  Google Scholar 

Saxena S, Zou L. Hallmarks of DNA replication stress. Mol Cell. 2022;82(12):2298–314.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Allison Stewart C, Tong P, Cardnell RJ, Sen T, Li L, Gay CM, Masrorpour F, Fan Y, Bara RO, Feng Y, et al. Dynamic variations in epithelial-to-mesenchymal transition (EMT), ATM, and SLFN11 govern response to PARP inhibitors and cisplatin in small cell lung cancer. Oncotarget. 2017;8(17):28575–87.

Article  CAS  PubMed  Google Scholar 

Barayan R, Ran X, Lok BH. PARP inhibitors for small cell lung cancer and their potential for integration into current treatment approaches. J Thorac Dis. 2020;12(10):6240–52.

Article  PubMed  PubMed Central  Google Scholar 

Gardner EE, Lok BH, Schneeberger VE, Desmeules P, Miles LA, Arnold PK, Ni A, Khodos I, de Stanchina E, Nguyen T, et al. Chemosensitive relapse in small cell lung cancer proceeds through an EZH2-SLFN11 axis. Cancer Cell. 2017;31(2):286–99.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Inno A, Stagno A, Gori S. Schlafen-11 (SLFN11): a step forward towards personalized medicine in small-cell lung cancer? Transl Lung Cancer Res. 2018;7(Suppl 4):S341–5.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Knelson EH, Patel SA, Sands JM. PARP inhibitors in small-cell lung cancer: rational combinations to improve responses. Cancers (Basel). 2021. https://doi.org/10.3390/cancers13040727.

Article  PubMed  Google Scholar 

Krushkal J, Silvers T, Reinhold WC, Sonkin D, Vural S, Connelly J, Varma S, Meltzer PS, Kunkel M, Rapisarda A, et al. Epigenome-wide DNA methylation analysis of small cell lung cancer cell lines suggests potential chemotherapy targets. Clin Epigenetics. 2020;12(1):93.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Kundu K, Cardnell RJ, Zhang B, Shen L, Stewart CA, Ramkumar K, Cargill KR, Wang J, Gay CM, Byers LA. SLFN11 biomarker status predicts response to lurbinectedin as a single agent and in combination with ATR inhibition in small cell lung cancer. Transl Lung Cancer Res. 2021;10(11):4095–105.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Lok BH, Gardner EE, Schneeberger VE, Ni A, Desmeules P, Rekhtman N, de Stanchina E, Teicher BA, Riaz N, Powell SN, et al. PARP inhibitor activity correlates with SLFN11 expression and demonstrates synergy with temozolomide in small cell lung cancer. Clin Cancer Res. 2017;23(2):523–35.

Article  CAS  PubMed  Google Scholar 

Pietanza MC, Waqar SN, Krug LM, Dowlati A, Hann CL, Chiappori A, Owonikoko TK, Woo KM, Cardnell RJ, Fujimoto J, et al. Randomized, double-blind, phase II study of temozolomide in combination with either veliparib or placebo in patients with relapsed-sensitive or refractory small-cell lung cancer. J Clin Oncol. 2018;36(23):2386–94.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Pongor LS, Tlemsani C, Elloumi F, Arakawa Y, Jo U, Gross JM, Mosavarpour S, Varma S, Kollipara RK, Roper N, et al. Integrative epigenomic analyses of small cell lung cancer cells demonstrates the clinical translational relevance of gene body methylation. iScience. 2022;25(11):105338.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Chen H, Deng C, Gao J, Wang J, Fu F, Wang Y, Wang Q, Zhang M, Zhang S, Fan F, et al. Integrative spatial analysis reveals tumor heterogeneity and immune colony niche related to clinical outcomes in small cell lung cancer. Cancer Cell. 2025;43(3):519-536.e515.

Article  CAS  PubMed  Google Scholar 

Coussy F, El-Botty R, Château-Joubert S, Dahmani A, Montaudon E, Leboucher S, Morisset L, Painsec P, Sourd L, Huguet L, et al. BRCAness, SLFN11, and RB1 loss predict response to topoisomerase I inhibitors in triple-negative breast cancers. Sci Transl Med. 2020. https://doi.org/10.1126/scitranslmed.aax2625.

Article  PubMed  PubMed Central